Global Gastric Cancer Diagnostics Market size and share is currently valued at USD 1.33 billion in 2024 and is anticipated to generate an estimated revenue of USD 2.78 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 7.7% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034

Market Overview

Gastric cancer, also known as stomach cancer, remains a significant global health challenge, particularly in parts of Asia, Eastern Europe, and Latin America. Despite advancements in treatment, survival rates remain low due to late-stage diagnosis, underscoring the critical role of early detection. The gastric cancer diagnostics market encompasses a range of technologies and procedures used to identify malignant changes in the stomach lining, including endoscopy, biopsy, imaging techniques, blood-based biomarker tests, and molecular diagnostics.

Diagnostic methods such as upper gastrointestinal endoscopy with biopsy continue to serve as the gold standard, enabling direct visualization and tissue sampling. However, the integration of non-invasive and minimally invasive approaches—such as serum pepsinogen testing, Helicobacter pylori screening, and circulating tumor DNA (ctDNA) analysis—is transforming the diagnostic pathway, offering faster, scalable, and patient-friendly alternatives.

The market includes products such as diagnostic kits, imaging equipment, laboratory services, and software solutions for data interpretation. As precision medicine gains traction, molecular profiling and genomic testing are becoming integral to both diagnosis and treatment planning.

Growth Drivers

A primary factor fueling market expansion is the increasing global burden of gastric cancer, particularly in high-prevalence regions where risk factors such as H. pylori infection, dietary habits, smoking, and genetic predisposition are widespread. Public health campaigns aimed at early screening and eradication of H. pylori are contributing to higher diagnostic volumes.

Technological innovation is another major driver. The development of liquid biopsy technologies, artificial intelligence-powered endoscopic imaging, and next-generation sequencing (NGS) platforms has enhanced the accuracy and efficiency of gastric cancer detection. AI-assisted endoscopy, for example, enables real-time identification of precancerous lesions, improving diagnostic sensitivity and reducing human error.

Additionally, rising healthcare expenditure, improved access to medical facilities, and government-backed cancer screening programs are facilitating broader adoption of diagnostic services. In countries like Japan and South Korea, where national screening initiatives have been implemented for decades, early detection rates are significantly higher, serving as a model for other nations.

Major Key Players:

• Abbott Laboratories
• Agilent Technologies, Inc.
• AI Medical Service Inc.
• BIOMÉRIEUX
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd. (Roche)
• Illumina, Inc.
• Mirxes Pte. Ltd.
• Myriad Genetics, Inc.
• QIAGEN
• Vela Diagnostics

Challenges and Opportunities

Despite progress, the gastric cancer diagnostics market faces several challenges. Limited access to advanced diagnostics in low- and middle-income countries, lack of standardized screening protocols, and low public awareness remain barriers to widespread early detection. Additionally, the invasive nature of traditional endoscopy can deter patient compliance, particularly in asymptomatic individuals.

However, these challenges present substantial opportunities for innovation and market expansion. The growing demand for non-invasive testing methods has spurred research into blood-based biomarkers, breath tests, and urine assays that could enable population-level screening. Point-of-care testing and portable endoscopic devices are also being developed to improve accessibility in rural and underserved areas.

Furthermore, collaborations between diagnostic companies, academic institutions, and healthcare providers are fostering the development of integrated diagnostic platforms. The emergence of telepathology and digital pathology solutions is enabling remote analysis of biopsy samples, expanding diagnostic reach and efficiency.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/gastric-cancer-diagnostics-market

Market Segmentation

The gastric cancer diagnostics market is segmented by diagnostic method, product type, end user, and application. By method, the market includes endoscopy, biopsy, imaging (CT, MRI, PET scans), serological testing, and molecular diagnostics. Endoscopy and biopsy collectively hold the largest share due to their diagnostic accuracy and widespread clinical use.

Product types encompass instruments, reagents and kits, and software. Reagents and kits used in biomarker detection and molecular profiling are witnessing rapid growth, driven by the shift toward personalized medicine.

End users include hospitals, diagnostic laboratories, endoscopy centers, and research institutions. Hospitals remain the primary setting for gastric cancer diagnosis, though specialized diagnostic centers are gaining prominence.

Applications span screening, diagnosis, prognosis, and treatment monitoring. Screening and early diagnosis represent the fastest-growing segments, reflecting the emphasis on preventive care.

Regional Analysis

The Asia-Pacific region dominates the gastric cancer diagnostics market, driven by high disease prevalence in countries such as China, Japan, and South Korea. These nations have well-established screening programs and advanced healthcare infrastructure, contributing to higher diagnostic volumes.

North America follows in market share, supported by technological innovation, robust reimbursement policies, and growing investments in cancer research. The United States is a key hub for the development of novel diagnostic platforms and biomarker discovery.

Europe shows steady growth, with countries like Germany, France, and the UK expanding their cancer screening initiatives. The presence of strong regulatory frameworks supports the adoption of high-quality diagnostic solutions.

Latin America, the Middle East, and Africa are emerging markets with significant potential, as governments and healthcare organizations work to improve cancer detection infrastructure and public awareness.

Summary

The gastric cancer diagnostics market is undergoing transformative growth, shaped by technological advancements, rising disease burden, and global efforts to promote early detection. While challenges in accessibility and awareness persist, opportunities in non-invasive testing, AI integration, and point-of-care diagnostics are paving the way for more effective and scalable solutions. As the world moves toward precision oncology, the role of advanced diagnostics in improving gastric cancer outcomes will continue to expand, offering hope for earlier intervention and better survival rates.

More Trending Latest Reports By Polaris Market Research:

Ultrasound Needle Guides Market

Dental Service Organization Market

Wireless Gigabit Market

Luxury Furniture Market

Trim Tabs Market

Smart City Platforms Market

Anti-Snoring Devices And Snoring Surgery Market

Silicon Photonics Market

Luxury Furniture Market